Type 2 diabetes results from the progressive alteration of the endocrine function (insulin secretory) of the pancreatic beta cells as well as pancreatic endocrine inability to compensate peripheral insulin resistance. It is a chronic and progressive pathology that requires a lifetime monitoring and surveillance with a therapeutic scaling, regarding the drug therapy.
Incretins are a new class of drugs that enriches the therapeutic arsenal already available to treat type 2 diabetes which is not fully satisfactory because it does not affect weight loss nor improves Î² cells function. Incretins are a promising therapeutic option because they improve glycemic control, induce weight loss of about 2-3 kg/year and offer the hope of a stabilization or improvement of Î² cells function by promoting proliferation and inhibiting apoptosis of Î² cells.
Position of Incretin Agents in the Traitement of Type 2 Diabetes Mellitus:
Literature Review :Sara Deghima, Smina Yahiaoui and Aissa Boudiba
Last date updated on April, 2021